Hepatitis Flashcards
(25 cards)
Hbsag becomes undetectable _____ after onset of jaundice
after 1-2 mos
When does antiHBc appear in the serum
Within the first 1-2 weeks after appearance of HBsAg
HbsAg levels detectable when
Within 1-12 weeks
HCV gains entry into the hepatocytes through this receptor
CD81 receptors
claudin-1
Most sensitive HCV infection
HCV RNA
Entirely transmitted NonA NonB hepatitis
Hep E
extrahepatic manifestations of Hep
serum-sickness like syndrome
GN
generalized vasculitis
essential mixed cryoglobulinemia
Hep B; arthritis, cutaneous vasculitis (palpable purpura) +/- GN with circulating cryoprecipitable immune complexes of more than one immunoglobulin class
essential mixed cryoglobulinemia
acidophilic degeneration of hepatocytes
councilman/apoptptic bodies
Liver damage in hepatitis
- hepatitis cell degeneration and necrosis
- cell dropout
- ballooning of cells
- acidophilic degeneration of hepatocytes
Large hepatocytes with ground glass appearance
chronic hepatitis
paucity of inflammation
increase in activation of sinusoidal lining cells
lymphoid aggregate
Hepa C
Hepatitis
microvesicular steatosis
Hepa D
common histologic feature is marked cholestasis
Hep E
Component of the “bridge”
- condensed reticulum
- inflammatory debris
- degenerating liver cells that span adjacent portal areas
fulminant hepatitis
“acute yellow atrophy”
massive hepatic necrosis
subacute or confluent necrosis
interface hepatitis
bridging hepatic necrosis
AE of interferon therapy for Hepa B that is not reversible upon dose lowering
Autoimmune hepatitis
High risk individuals that should receive screening for hep B
CHIMPA h-3 i-3 m-2
Countries endemic Household contacts HCV/HIV patients HD patients Inmates Injection drugs Immunosuppressed MSM Multiple sex contacts Pregnant ALT or AsT elevated
Jaundice in sclera
> 43 umol or 2.5 mg/dl
First approved therapy for hepa B
Interferon
MOA lamivudine
Inhibits reverse transcriptase activity of HIV and HBV
Monotherapy of ____ can induce YMDD variants in patients with HIV infection
Lamivudine
First line therapy of choice in HBeAg reactive chronic hepatitis B
PEG IFN monotheraoy